A Letter from the NRG Oncology Group Chairs on Rare Tumor Trials

September 19 2019

Dear NRG Principal Investigators,

We were recently asked to provide a letter to support an NRG Oncology investigator’s response to a query at their institution related to a study not meeting the accrual threshold for remaining open. You likely have some experience with being questioned about maintaining an open study that doesn’t appear to be accruing due to the rare-tumor type involved.  We agreed to pull together a letter to provide support, and thought to share this more broadly. 

We appreciate the challenge arising from keeping studies open that don’t appear to be accruing well locally, and hope that in the case of rare-tumor types exceptions are made.  We are very willing to support your local efforts, however it is important to ensure every eligible patient has an opportunity to participate. 

We hope this is helpful, and appreciate your commitment to NRG Oncology.


Walter J. Curran, Jr., MD
Robert Mannel, MD
Norman Wolmark, MD

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.